Literature DB >> 21720207

The follow-up of radioiodine-treated hyperthyroid patients: should thyroid function be monitored more frequently?

S R Peacey1, S Kumar, D Wright, R King.   

Abstract

BACKGROUND: There is a lack of data regarding the timing and particularly the severity of hypothyroidism post radioiodine (RI). AIM: To investigate the timing and severity of hypothyroidism in RI-treated hyperthyroid patients.
METHODS: Retrospective examination of the records of 183 RI-treated hyperthyroid patients (79 autoimmune hyperthyroidism, 46 toxic multinodular goiter, and 58 hyperthyroidism of indeterminate etiology).
RESULTS: One hundred and fifty-nine patients requiring a single dose of RI (435 MBq), 107 (67%) developed hypothyroidism. Hypothyroidism detected in: 16% of patients at <8 weeks, 46% at 8 to <16 weeks, 24% at 16 to <24 weeks, 9% at 24 to <36 weeks, 3% at 36 to <52 weeks, and 2% at >52 weeks. One hundred and eighty-three patients had follow-up after one or more doses of RI and 124 (68%) patients developed hypothyroidism; of these, 44 (36%) had TSH>50 mU/l and 34 (27%) had free T4<5 pmol/l when hypothyroidism was first detected. Of those patients with a delayed outpatient visit (no.=77) and those with an outpatient visit within the recommended target interval (no.=47), median TSH was 23 (0.05-152) mU/l and 32 (0.05-150) mU/l, respectively (p=0.75) and median free T4 was 7.1 (1.3-16.7) pmol/l and 6.6 (1.3-15.4) pmol/l, respectively (p=0.21) at first detection of hypothyroidism.
CONCLUSIONS: The severity of hypothyroidism when first detected during follow-up is of concern and suggests that closer monitoring of thyroid function is required, particularly during the first 6 months post- RI therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720207     DOI: 10.3275/7807

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials.

Authors:  Martin A Walter; Matthias Briel; Mirjam Christ-Crain; Steen J Bonnema; John Connell; David S Cooper; Heiner C Bucher; Jan Müller-Brand; Beat Müller
Journal:  BMJ       Date:  2007-02-19

2.  The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.

Authors:  Y Aizawa; K Yoshida; N Kaise; H Fukazawa; Y Kiso; N Sayama; H Hori; K Abe
Journal:  Clin Endocrinol (Oxf)       Date:  1997-01       Impact factor: 3.478

3.  An evaluation of nurse-led rheumatology telephone clinics.

Authors:  Sheena Hennell; Eileen Spark; Barbara Wood; Emmanuel George
Journal:  Musculoskeletal Care       Date:  2005

4.  The cost effectiveness of treatment modalities for thyrotoxicosis in a U.K. center.

Authors:  N N Patel; P Abraham; J Buscombe; M P J Vanderpump
Journal:  Thyroid       Date:  2006-06       Impact factor: 6.568

5.  Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis.

Authors:  Aftab M Ahmad; Munir Ahmad; Eric T Young
Journal:  Eur J Endocrinol       Date:  2002-06       Impact factor: 6.664

6.  Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy.

Authors:  Masayuki Nakajo; Shinsaku Tsuchimochi; Hiroaki Tanabe; Yoshiaki Nakabeppu; Megumi Jinguji
Journal:  Ann Nucl Med       Date:  2005-06       Impact factor: 2.668

7.  Long-term follow-up study of radioiodine treatment of hyperthyroidism.

Authors:  Saara Metso; Pia Jaatinen; Heini Huhtala; Tiina Luukkaala; Heikki Oksala; Jorma Salmi
Journal:  Clin Endocrinol (Oxf)       Date:  2004-11       Impact factor: 3.478

8.  Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.

Authors:  M A Walter; C Schindler; M Christ-Crain; J Müller-Brand; B Müller
Journal:  Eur J Clin Invest       Date:  2009-01       Impact factor: 4.686

9.  Radioiodine treatment for benign thyroid diseases.

Authors:  Anthony P Weetman
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04-25       Impact factor: 3.478

10.  Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism.

Authors:  K Boelaert; A A Syed; N Manji; M C Sheppard; R L Holder; S C Gough; J A Franklyn
Journal:  Clin Endocrinol (Oxf)       Date:  2008-05-06       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.